License Agreements - Additional Information (Details) - USD ($)			1 Months Ended					12 Months Ended
	Mar. 28, 2022	Jan. 31, 2022	Jan. 31, 2023	Oct. 31, 2021	Mar. 31, 2021	Dec. 31, 2020	Apr. 30, 2020	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2020	Mar. 31, 2023	Oct. 06, 2022
Research And Development Arrangement Contract To Perform For Others [Line Items]
Research and development expense								$ 49,586,000	$ 86,129,000
Deferred revenue								$ 7,660,000
Common stock, shares issued								44,754,853	35,110,016
Common Stock, Value, Issued								$ 45,000	$ 34,000
Apexigen, Inc.
Research And Development Arrangement Contract To Perform For Others [Line Items]
Deferred revenue								7,700,000
Milestone and royalties payments received post acquisition								1,000,000
Esbatech Agreement
Research And Development Arrangement Contract To Perform For Others [Line Items]
Deferred revenue								7,700,000
Pfizer License Agreement
Research And Development Arrangement Contract To Perform For Others [Line Items]
Payment for license fee					$ 25,000,000
Common stock, shares issued											1,811,594	2,229,654
Royalty obligation period for licensed products upon first commercial sale						12 years
Milestone and royalties required								0	0
Upfront payments			$ 8,000,000		5,000,000
Pfizer License Agreement | Maximum
Research And Development Arrangement Contract To Perform For Others [Line Items]
Aggregate milestone payments for first four licensed products						$ 665,000,000
Pfizer License Agreement | IPO
Research And Development Arrangement Contract To Perform For Others [Line Items]
Number of common shares issued upon conversion of preferred stock				1,911,015
Pfizer License Agreement | Series B Convertible Preferred Stock
Research And Development Arrangement Contract To Perform For Others [Line Items]
Issuance of convertible preferred stock shares				12,152,145
Issuance of convertible preferred stock value				$ 20,000,000
LegoChem License Agreement
Research And Development Arrangement Contract To Perform For Others [Line Items]
Estimated cost to purchase licensed products								7,000,000
Milestone and royalties required								0
Stock option upfront payments										$ 8,000,000
Extra milestone payment						$ 9,600,000
Extra milestone payment for which derivative liability recognized		$ 9,600,000
LegoChem License Agreement | Research and Development Expenses
Research And Development Arrangement Contract To Perform For Others [Line Items]
Upfront fee					$ 9,000,000
Biosion License Agreement
Research And Development Arrangement Contract To Perform For Others [Line Items]
Aggregate maximum obligation to pay future contingent milestone payments for normal approval	$ 217,500,000
Aggregate maximum obligation to pay future contingent milestone payments for accelerated approval	$ 222,500,000
Royalty obligation period for licensed products upon first commercial sale	12 years
Milestone and royalties required								0	0
Biosion License Agreement | Research and Development Expenses
Research And Development Arrangement Contract To Perform For Others [Line Items]
Upfront fee	$ 10,000,000
Simcere License Agreement
Research And Development Arrangement Contract To Perform For Others [Line Items]
Royalty obligation period for licensed products upon after first commercial sale						15 years
Milestone and royalties receivable								0
Mabwell Agreement
Research And Development Arrangement Contract To Perform For Others [Line Items]
Milestone and royalties receivable								$ 0
Toray Sublicense Agreement
Research And Development Arrangement Contract To Perform For Others [Line Items]
Royalty obligation period for licensed products upon after first commercial sale								10 years
Milestone and royalties receivable								$ 0
University License Agreement
Research And Development Arrangement Contract To Perform For Others [Line Items]
Common stock issued to university							48,919
Milestone and royalties required								$ 0	$ 0
University License Agreement | Maximum
Research And Development Arrangement Contract To Perform For Others [Line Items]
Potential development and commercial milestones							$ 7,700,000
Minimum annual royalty fees							$ 3,000,000